GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (FRA:1KA) » Definitions » Additional Paid-In Capital

GH Research (FRA:1KA) Additional Paid-In Capital : €268.15 Mil(As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is GH Research Additional Paid-In Capital?


GH Research's quarterly additional paid-in capital declined from Sep. 2023 (€273.09 Mil) to Dec. 2023 (€267.27 Mil) but then increased from Dec. 2023 (€267.27 Mil) to Mar. 2024 (€268.15 Mil).

GH Research's annual additional paid-in capital increased from Dec. 2021 (€257.93 Mil) to Dec. 2022 (€275.13 Mil) but then declined from Dec. 2022 (€275.13 Mil) to Dec. 2023 (€267.27 Mil).


GH Research Additional Paid-In Capital Historical Data

The historical data trend for GH Research's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GH Research Additional Paid-In Capital Chart

GH Research Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
- 4.46 257.93 275.13 267.27

GH Research Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 272.21 269.01 273.09 267.27 268.15

GH Research Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

GH Research Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of GH Research's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


GH Research (FRA:1KA) Business Description

Traded in Other Exchanges
Address
28 Baggot Street Lower, Dublin, IRL, D02 NX43
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Its focus is on developing novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.

GH Research (FRA:1KA) Headlines

No Headlines